Please login to the form below

Triple-negative breast cancer

This page shows the latest Triple-negative breast cancer news and features for those working in and with pharma, biotech and healthcare.

Gilead agrees $21bn buyout of Immunomedics

treatment of metastatic triple-negative breast cancer (mTNBC). ... The ADC is also being studied in an ongoing phase 3 trial in third line HR+/HER2-positive breast cancer, and a registrational phase 2 study in bladder cancer.

Latest news

Merck signs separate agreements with Seattle Genetics for two cancer drugs

As part of this expansive clinical programme, Merck and Seattle Genetics are set to investigate ladiratuzumab vedotin in a number of additional cancer types, including triple-negative breast cancer, hormone ... Tukysa was approved by the US Food and Drug
Tecentriq combo fails in advanced triple negative breast cancer

Tecentriq plus paclitaxel failed to improve progression-free survival. Roche’s hopes of extending its PD-L1 inhibitor Tecentriq into metastatic triple negative breast cancer (TNBC) have fallen flat after the ... TNBC is an aggressive and hard-to-treat
AZ strengthens Daiichi Sankyo partnership with new ADC deal

Last December, the therapy was approved by the US Food and Drug Administration (FDA) for the treatment of metastatic HER2-positive breast cancer in patients who have been previously treated with ... DS-1062 could also cover more ground for AZ and open up
AZ’s Imfinzi gets US OK in small cell lung cancer, challenging Tecentriq

which is more common than SCLC – as well as bladder cancer and triple-negative breast cancer. ... patients whose tumours are not able to be surgically removed, and whose cancer has not progressed after treatment with chemo and radiation therapy.
Merck chases Roche with triple-negative breast cancer data for Keytruda

Data demonstrated a delay in disease progression or death. Merck &Co/MSD has chalked up a clinical trial win for its PD-1 inhibitor Keytruda in triple-negative breast cancer that ... TNBC is an aggressive and hard-to-treat subtype of breast cancer,

More from news
Approximately 4 fully matching, plus 63 partially matching documents found.

Latest Intelligence

Cortellis Drugs to Watch in 2020 report

9. Immunomedic’s sacituzumab govitecan initial target market is metastatic triple negative breast cancer in patients who have failed at least two prior therapies. ... It is approved in the US for the treatment of unresectable or metastatic
Deal Watch January 2018

The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer ... that is highly selective for HER2
Deal Watch February 2017

triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. . ... Acquisition - company. 2, 475. Immunomedics/ Seattle Genetics. IMMU-132 (sacituzumab govitecan), an antibody drug
Pharma deals during February 2014

awarded FDA breakthrough therapy status for advanced melanoma last year, and is being studied in 13 clinical trials across more than 30 types of cancer. Financial terms for these deals were ... BATON studies in colorectal cancer and metastatic triple

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

July 2020: diversity and inclusion in clinical trials round-up

The shocking stats surrounding black women and health outcomes. Alarmingly, although black women are overall less likely to develop breast cancer, they’re 40% more likely to die from it compared ... Black women are at higher risk for a type of
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)

cell carcinoma, Merkel cell carcinoma, and triple-negative breast cancer (TNBC) via chest-wall lesions.8. ... 2018; 15(10):599-616. National Cancer Institute. Surveillance, Epidemiology, and End Results Program.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Surviving cancer: a new era for patients: Now more than ever, a shift in perspective is needed...
Crisis? No problem!: Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?: First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....